Vanguard Global Advisers
CHRS icon

Vanguard Global Advisers’s Coherus Oncology CHRS Stock Holding History

Vanguard Global Advisers’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.9K Hold
57,809
– – ﹤0.01% 2873
2026
Q1 		$97.7K Buy
+57,809
New +$103K ﹤0.01% 2741

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Vanguard Global Advisers's CHRS Position: Q2 2026 in Review

Vanguard Global Advisers held its Coherus Oncology (CHRS) position steady in Q2 2026 at 57,809 shares worth $80.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2873.

Vanguard Global Advisers first reported a position in CHRS in Q1 2026 and has held it in 2 quarters since. The position peaked at $97.7K in Q1 2026. 145 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Vanguard Global Advisers held 57,809 shares of Coherus Oncology worth $80.9K as of Q2 2026.
  • Vanguard Global Advisers left its Coherus Oncology share count unchanged in Q2 2026.
  • Coherus Oncology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2873 holding.
  • Vanguard Global Advisers first reported a position in Coherus Oncology in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Coherus Oncology position peaked at $97.7K in Q1 2026.
  • 145 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.